Physician profile
Dan Muntean
NPI 1164413761
$7,745.77
in general payments reported to CMS, 2019-2025
41 companies · $1,181 in 2025
The $1,181 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,521 · 2020: $1,431 · 2021: $1,419 · 2022: $585 · 2023: $717 · 2024: $891 · 2025: $1,181.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,790.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,789.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $990.31 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals Lp | $952.13 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $672.29 | 2019-2025 | |
| Abbvie INC. | $671.23 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $474.68 | 2019-2025 | Trintellix |
| Novo Nordisk INC | $444.61 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $371.35 | 2019-2024 | Spiriva Respimat, Ofev, Stiolto Respimat |
| Lilly USA, LLC | $359.59 | 2019-2025 | Mounjaro, Trulicity, Jardiance |
| Amarin Pharma, INC. | $336.57 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $316.40 | 2019-2022 | |
| Amgen INC. | $311.17 | 2019-2025 | Otezla, Repatha, Repatha |
| Allergan, INC. | $262.90 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $248.79 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $162.88 | 2021-2024 | Rexulti |
| Boston Scientific Corporation | $140.10 | 2025 | Wavewriter Alpha Prime 16 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dan Muntean listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.